Understanding Parkinson's Disease
A comprehensive, evidence-based guide covering diagnosis, treatments, cutting-edge research, lifestyle strategies, and global support networks. Updated with the latest clinical findings.
Navigate the Portal
What Is Parkinson's Disease?
Understanding the biology, symptoms, and causes
The Biology of PD
Parkinson's disease is a progressive neurodegenerative disorder caused by the gradual loss of dopamine-producing neurons in the Substantia Nigra — a region deep in the brainstem. Dopamine is essential for smooth, coordinated movement.
A hallmark of PD is the accumulation of alpha-synuclein protein into toxic clumps called Lewy bodies. When dopamine levels drop by approximately 80%, motor symptoms begin to appear.
Core Motor Symptoms
- Tremor — Rhythmic shaking, most commonly in the hand at rest
- Rigidity — Muscle stiffness, resistance to passive movement
- Bradykinesia — Slowness of movement, reduced arm swing
- Postural instability — Balance problems, increased fall risk
- Freezing of gait — Sudden inability to initiate movement
- Masked face — Reduced facial expressiveness
Non-Motor Symptoms
- Depression and anxiety (very common, often precede motor onset)
- REM sleep behavior disorder
- Cognitive changes; dementia in late stages
- Constipation and digestive issues
- Loss of smell (anosmia) — often precedes motor symptoms by years
- Fatigue and autonomic dysfunction
- Pain and sensory disturbances
Age: The strongest risk factor — most people are diagnosed after age 60. Early-onset PD (before 50) affects about 5-10% of patients.
Genetics: About 10-15% of cases have a clear genetic cause. Key genes include LRRK2, PINK1, Parkin, SNCA, and GBA1. GBA1 variants are the most common genetic risk factor worldwide.
Environmental factors: Prolonged exposure to pesticides, herbicides (rotenone and paraquat), and heavy metals may increase risk. Rural living and well water use have been associated with higher rates in multiple studies.
Protective factors: Regular vigorous exercise, caffeine consumption, and higher uric acid levels have been associated with reduced PD risk in epidemiological studies.
Parkinson's disease is primarily a clinical diagnosis based on bradykinesia plus at least one of: resting tremor, rigidity, or a positive response to dopaminergic therapy.
- MDS-UPDRS Scale: The gold-standard tool for measuring motor and non-motor symptom severity
- DaTscan (SPECT): Neuroimaging to detect dopamine transporter deficits in the striatum
- MRI: Used to rule out other conditions; not diagnostic for PD itself
- Alpha-synuclein SAA: A new blood/CSF biomarker with high sensitivity that may allow earlier diagnosis
- Smell testing: Anosmia is present in approximately 90% of PD patients
Treatments
Medications, advanced therapies, and side effect management
| Drug (Brand Name) | Class | How It Works | Notes |
|---|---|---|---|
| Levodopa/Carbidopa (Sinemet) | Dopamine precursor | Converts to dopamine in the brain; carbidopa prevents peripheral breakdown | Gold standard; most effective. May cause dyskinesias over time. |
| Pramipexole (Mirapex) | Dopamine agonist | Mimics dopamine by binding to its receptors | Often used in early PD; risk of impulse control disorders |
| Ropinirole (Requip) | Dopamine agonist | Mimics dopamine activity in the brain | Similar profile to pramipexole; available in extended-release form |
| Rasagiline (Azilect) | MAO-B inhibitor | Slows breakdown of dopamine in the brain | Can be used as monotherapy or add-on; possible mild neuroprotective signal |
| Entacapone (Comtan) | COMT inhibitor | Prolongs levodopa effect by blocking its peripheral breakdown | Always used with levodopa; extends "on" time |
| Amantadine (Symmetrel/Gocovri) | NMDA antagonist | Reduces dyskinesias; mild dopaminergic effect | Gocovri (extended-release) FDA-approved specifically for dyskinesia |
| Safinamide (Xadago) | MAO-B inhibitor + glutamate blocker | Dual action: increases dopamine and reduces glutamate excitotoxicity | Add-on therapy; approved for fluctuating PD |
Deep Brain Stimulation (DBS)
The most established surgical intervention for PD. Electrodes implanted in the subthalamic nucleus (STN) or globus pallidus (GPi) deliver electrical pulses that regulate abnormal brain activity. Effective for tremor, rigidity, and motor fluctuations. Next-generation adaptive DBS (Medtronic BrainSense) adjusts stimulation in real time based on brain signals.
Duopa / Duodopa Pump
Continuous intestinal infusion of levodopa-carbidopa gel via a surgically placed tube. Provides more stable drug levels than oral pills, significantly decreasing "off" time by up to 4-5 hours per day. Effective for advanced PD with significant motor fluctuations.
Focused Ultrasound (FUS)
A non-invasive procedure using focused sound waves to create a precise thermal lesion in the thalamus or subthalamic nucleus. FDA-approved for essential tremor and tremor-dominant PD. No incision required. The Exablate Neuro system is the leading device; bilateral treatment studies are ongoing.
Gene Therapy (Emerging)
Multiple gene therapy approaches are in clinical trials: AAV vectors delivering AADC to improve levodopa conversion, and neuroprotective approaches targeting alpha-synuclein, LRRK2, and GBA1. The REGENERATE-PD trial (NCT06285643) is evaluating AAV gene therapy for GBA1-PD patients.
After years of levodopa treatment, many patients experience:
- "Wearing off": Benefits fade before the next dose; "off" periods increase in frequency and severity
- Dyskinesias: Involuntary, writhing movements that occur at peak levodopa levels
- "On-off" fluctuations: Sudden, unpredictable swings between mobility and freezing
Management options: Smaller, more frequent doses; sustained-release formulations; adding amantadine (Gocovri); advanced device therapies (DBS, Duopa).
Dopamine agonists (pramipexole, ropinirole) carry a risk of impulse control disorders in approximately 1 in 6 patients, including:
- Pathological gambling
- Hypersexuality
- Binge eating
- Compulsive shopping or hoarding
- Dopamine dysregulation syndrome (compulsive medication overuse)
Report any of these behaviors to your neurologist immediately. Dose reduction or medication change usually resolves the disorder.
- Nausea: Common with levodopa — take with food or with a carbidopa add-on
- Orthostatic hypotension: Dizziness when standing — manage with hydration, compression stockings
- Hallucinations/psychosis: More common in advanced PD — Pimavanserin (Nuplazid) is FDA-approved specifically for PD psychosis without worsening motor symptoms
- Excessive daytime sleepiness: Can occur with dopamine agonists — caution when driving
- Edema: Ankle and leg swelling with agonists
Key Questions to Ask
- Should I start medication now or monitor first?
- Should I see a movement disorder specialist?
- Am I a candidate for DBS or other device therapies?
- Should I have genetic testing (LRRK2, GBA1)?
- What clinical trials am I eligible for?
- Do you use the MDS-UPDRS to track my progress?
The Multidisciplinary Team
Optimal PD care involves a team of specialists:
- Movement disorder neurologist — core PD management
- Physiotherapist — movement, balance, gait rehabilitation
- Speech-language pathologist — speech and swallowing
- Occupational therapist — daily activities, home safety
- Psychologist/psychiatrist — mood, cognition, behavioral issues
- Dietitian — nutrition, protein timing with levodopa
- Specialist nurse — medication management, patient education
Clinical Trials
Active and recruiting trials worldwide — as of 2024/2025
VacSYn — Alpha-Synuclein Vaccine (NCT06015841)
A first-in-class therapeutic vaccine designed to generate antibodies against alpha-synuclein aggregates. Phase 1/2 trial testing safety and immune response. This disease-modifying approach targets the root pathology of PD.
REGENERATE-PD — Gene Therapy for GBA1-PD (NCT06285643)
AAV-based gene therapy delivering a functional GBA1 gene to neurons in patients with GBA1 mutations — the most common genetic form of PD. Phase 1/2 safety trial. A corrective gene therapy could significantly slow progression in this subgroup.
Prasinezumab — Anti-Alpha-Synuclein Antibody (Roche/Prothena)
Phase 2b PADOVA trial in early-stage PD patients. The antibody targets and clears pathological alpha-synuclein. Early signals showed possible slowing of motor progression in fast-progressing patients. Phase 2b results expected 2025.
GLP-1 Receptor Agonists — Lixisenatide and Semaglutide
GLP-1 drugs originally developed for diabetes have shown neuroprotective effects in PD. A French Phase 2 trial of lixisenatide (Lancet, 2023) showed significantly less motor decline versus placebo. Multiple larger trials with semaglutide are ongoing.
LUMA Study — LRRK2 Inhibitor (NCT06602193)
Evaluating BIIB122 (DNL151), an oral LRRK2 kinase inhibitor, in patients with LRRK2-mutation PD. LRRK2 is the most common mutation in familial PD. Phase 2/3 — one of the most promising precision medicine approaches in PD research.
ACTIVATE — GBA1-Targeted Therapy (Ambroxol)
Testing ambroxol and other GBA1-enhancing strategies to restore lysosomal function in GBA1-PD patients. Ambroxol has shown early promise by increasing GCase enzyme activity and reducing alpha-synuclein accumulation.
iPSC Stem Cell Therapy — Harvard/Brigham Study
Phase 1 trials of dopaminergic neurons derived from induced pluripotent stem cells implanted in the striatum. Safety data in 2023-2024 showed cells survived and began producing dopamine. Could eventually offer cell replacement therapy for PD.
Adaptive DBS — Medtronic BrainSense
Records local field potentials from implanted electrodes and uses them to automatically adjust stimulation in real time. Phase 3 clinical evaluations are ongoing. Aims to reduce side effects and extend battery life versus conventional open-loop DBS.
Finding a Trial
- Fox Trial Finder (foxtrialfinder.michaeljfox.org) — PD-specific, easy to use
- ClinicalTrials.gov — complete US and international trial registry
- EU Clinical Trials Register — European trials database
- WHO ICTRP — global registry network
- Ask your movement disorder neurologist directly
The Enrollment Process
- Review eligibility criteria (age, disease stage, medications)
- Contact the trial coordinator by email or phone
- Attend a screening visit — usually covered by the trial
- Receive full informed consent documentation
- You can withdraw at any time without affecting your regular care
Who Can Participate?
Different trials need different participants:
- Newly diagnosed patients (disease-modifying trials)
- People with specific gene mutations (LRRK2, GBA1, PINK1)
- Advanced PD patients (device therapies)
- Healthy relatives of PD patients (genetic risk studies)
- Older adults without PD (prevention trials)
Latest Research
Breakthroughs from 2023-2025
Exercise Restores Neurons
A landmark Yale 2024 study (Bhatt et al.) demonstrated that intense aerobic exercise can restore the brain's dopaminergic system — not just slow its decline. Treadmill training increased BDNF expression and partially regenerated dopaminergic pathways in animal models, with human neuroimaging studies ongoing.
Lancet 2024 58% motor improvement
GLP-1 Drugs Show Promise
Diabetes drugs like lixisenatide and semaglutide (Ozempic) have emerged as potential neuroprotective agents for PD. A 2023 Lancet trial showed lixisenatide slowed motor progression compared to placebo. GLP-1 receptors in the brain may protect dopamine neurons from inflammation and oxidative stress.
Gut-Brain Axis
Growing evidence suggests PD may begin in the gut for many patients — alpha-synuclein misfolding propagates from enteric neurons to the brainstem via the vagus nerve (Braak hypothesis). Gut microbiome studies and appendix surgery data are revealing new targets for early intervention.
Biomarker Breakthrough: SAA
The alpha-synuclein seed amplification assay (SAA) can detect PD pathology in cerebrospinal fluid or skin biopsies with high sensitivity — years before motor symptoms appear. Blood-based versions are now being validated for easier clinical use, potentially enabling preventive treatment trials.
Stem Cell Advances
Multiple groups have demonstrated that iPSC-derived dopaminergic neurons can survive transplantation and integrate into primate and early human brains. Safety trials at Harvard/Brigham and Kyoto University show cell-replacement therapy may become realistic by the late 2020s.
Music Therapy and Neuroplasticity
A 2024 Cochrane meta-analysis confirmed that music therapy and rhythmic auditory stimulation (RAS) improve gait speed, stride length, and quality of life in PD. RAS uses an external rhythmic beat to help bypass basal ganglia dysfunction and restore walking automaticity.
Lifestyle Strategies
Exercise, nutrition, speech, and mental wellness
Rock Steady Boxing
Non-contact boxing program specifically developed for PD. Targets agility, speed, muscular endurance, balance, and hand-eye coordination. Available at 500+ affiliates in 30+ countries. Randomized trials show significant improvements in UPDRS scores, balance, and quality of life.
Intense Cycling (SPARX3)
The SPARX3 trial demonstrated that high-cadence cycling (80+ RPM) significantly outperformed moderate cycling for motor symptom improvement. Vigorous aerobic activity appears to have neuroprotective effects beyond fitness, possibly stimulating BDNF and dopamine release.
Tai Chi and Balance
Multiple RCTs confirm Tai Chi reduces falls by up to 55% in PD patients. The slow, intentional weight-shifting movements improve proprioception and postural stability. Recommended by the Parkinson's Foundation as a core exercise modality. Even two sessions per week shows measurable effects.
Tango and Dance
Argentine tango has been specifically studied in PD and shown to improve balance, spatial cognition, and gait. The rhythmic, partnered nature provides auditory and tactile cues that help bypass basal ganglia timing deficits. Dance therapy programs are available at many movement disorder centers worldwide.
Aquatic Therapy
Water buoyancy reduces fall risk while enabling vigorous exercise. Aquatic therapy improves balance, strength, and gait in PD. Warm water also helps with rigidity. Available at hydrotherapy pools at many rehabilitation centers and sports facilities.
Nordic Walking
Walking with poles engages the upper body, improves posture, reduces fall risk, and provides rhythmic bilateral movement patterns. Multiple studies show Nordic Walking improves gait speed, stride length, and balance in PD beyond standard walking.
Mediterranean Diet
The Mediterranean diet — fruits, vegetables, whole grains, fish, olive oil, nuts — has the strongest evidence for neuroprotection in PD. Regular adherence is associated with slower progression and better cognitive function. Anti-inflammatory foods actively support neuronal health.
Protein Redistribution Diet
Large neutral amino acids in protein compete with levodopa for brain absorption. In patients with motor fluctuations, distributing protein to the evening meal can significantly improve levodopa effectiveness throughout the day. Work with a PD dietitian to implement this safely.
Gut Microbiome and Probiotics
Constipation affects 80% of PD patients and is often a pre-motor symptom. A 2024 randomized trial found probiotic supplementation significantly improved constipation and modestly improved motor scores. Adequate fiber intake and hydration are foundational gut health strategies.
Supplements — Evidence Summary
| Supplement | Evidence Level | Rationale | Notes |
|---|---|---|---|
| Vitamin D3 | Moderate | PD patients commonly deficient; may slow progression | Check levels; aim for 40-60 ng/mL range |
| Omega-3 (DHA/EPA) | Moderate | Anti-inflammatory; neuroprotective in animal models | 2-4g/day; fish oil or algae-based |
| Curcumin | Low-Moderate | Anti-inflammatory; inhibits alpha-synuclein aggregation in vitro | Low bioavailability — use with piperine or liposomal forms |
| CoQ10 | Low | Mitochondrial support; early PD trial showed possible slowing | Phase 3 trial was negative; still used adjunctively |
| NAC (N-Acetyl Cysteine) | Low-Moderate | Glutathione precursor; IV form showed signal in PD study | Oral form less studied; 600mg twice daily typical |
| Vitamin B1 (Thiamine) | Low (Preliminary) | High-dose thiamine protocol reports improvements; mechanism unclear | Requires monitoring; do not self-administer high doses |
| Probiotics | Moderate | Improves constipation; potential gut-brain axis benefits | Multi-strain products; consistent daily use needed |
LSVT LOUD Therapy
Lee Silverman Voice Treatment (LSVT LOUD) is the gold standard speech therapy for PD. It targets the soft, monotone voice by training patients to speak at high vocal effort ("LOUD"). Four sessions per week for four weeks. Shown to maintain improvements for 2+ years in RCTs.
Swallowing Difficulties
Dysphagia affects up to 80% of PD patients and is a major cause of aspiration pneumonia — the leading cause of death in PD. A speech-language pathologist can assess swallowing function, recommend diet texture modifications, and teach compensatory swallowing techniques.
Assistive Communication
For advanced PD with significant dysarthria: speech amplifiers, voice banking (record your voice while still clear), speech-generating devices, and AAC apps. Voice banking should be done early — ModelTalker, VocaliD, and similar services allow you to build a synthetic voice from your own recordings.
Depression in PD
Depression affects approximately 40% of PD patients and is a core non-motor symptom, not just a reaction to diagnosis. It often precedes motor symptoms by years. SSRIs and SNRIs are the first-line pharmacological treatment. CBT combined with medication shows best outcomes. Exercise has well-documented antidepressant effects in PD.
Anxiety
Anxiety disorders affect 30-55% of PD patients and frequently co-occur with depression. Anxiety often worsens during "off" periods — making medication timing important. CBT is effective; some patients benefit from buspirone or supervised low-dose anxiolytics. Mindfulness-based approaches also show benefit.
Sleep Disorders
REM sleep behavior disorder (RBD) — acting out vivid dreams physically — is present in up to 50% of PD patients and often precedes motor onset by decades. Other sleep problems include insomnia, restless legs, sleep apnea, and excessive daytime sleepiness. Address sleep with a neurologist who specializes in sleep medicine.
Physiotherapy
Evidence-based movement therapies for Parkinson's disease
Neurological Physiotherapy
A physiotherapist with neurological specialization designs personalized programs addressing gait, balance, posture, transfers, and fall prevention. Assessment includes the Berg Balance Scale, Timed Up and Go (TUG) test, and gait analysis. Physiotherapy is most effective when intensive and sustained over time.
LSVT BIG
LSVT BIG applies the same high-amplitude, high-effort principle as LSVT LOUD but to movement. Trains large, exaggerated movements to counteract the small, shuffling patterns of PD. Four sessions per week for four weeks; RCTs show significant improvements in UPDRS motor scores, gait speed, and balance.
Rock Steady Boxing
RSB uses non-contact boxing drills to challenge speed, agility, coordination, and dual-tasking simultaneously. The competitive, social environment significantly increases long-term adherence. Available at 500+ certified affiliates worldwide. Benefits are sustained with continued participation.
Tai Chi
Multiple RCTs confirm Tai Chi reduces fall frequency by up to 55% in PD. The slow, deliberate weight shifting, turns, and stepping patterns directly target the core balance impairments of PD. The Yang Style 24-form is most studied. Even two sessions per week shows significant measurable effects.
Tango Dance Therapy
Argentine tango provides rhythmic cues, backward walking, turns, and partnered coordination. Studies from the Montreal Neurological Institute show improvements in balance, step length, and spatial memory. Tango classes adapted for PD are available at many movement centers and community programs worldwide.
Resistance Training
Progressive resistance training targeting lower limb and core strength reduces rigidity, improves functional capacity, and helps prevent sarcopenia (muscle loss) that accelerates disability in PD. Combined aerobic and resistance programs show superior outcomes to either approach alone.
Freezing of gait (FOG) is one of the most disabling and fall-inducing symptoms of advanced PD. External cues can bypass the basal ganglia and trigger movement:
- Auditory cueing: Rhythmic auditory stimulation — metronome, music — improves stride length and cadence
- Visual cueing: Lines on the floor, laser canes — "step over" the visual cue to initiate movement
- Attentional strategies: Consciously thinking about large steps, focusing attention on destination
- Anti-freezing devices: Wearable laser-cane devices (U-Step walker), vibrotactile stimulation devices
- Dual-task training: Practicing walking while talking or carrying objects — trains real-world walking challenges
Psychological Approach
Mental health, emotional wellbeing, and behavioral interventions
Prevalence of Mental Health Challenges
- Depression: Affects approximately 38% of PD patients
- Anxiety: Affects 30-55% of patients
- Apathy (loss of motivation): Affects 40-60% of patients
- Impulse control disorders: Approximately 1 in 6 patients on dopamine agonists
- Psychosis/hallucinations: 20-40% in advanced PD
- Mild cognitive impairment: 25-30%; dementia in 75-80% over disease course
Evidence-Based Psychotherapies
- CBT: Well-studied for depression and anxiety in PD — targets negative thought patterns and behavioral avoidance
- ACT (Acceptance and Commitment Therapy): Focuses on psychological flexibility and value-based living
- MBSR (Mindfulness-Based Stress Reduction): Reduces anxiety and improves quality of life; online programs available
- Interpersonal Therapy (IPT): Addresses grief, role transitions, and relationship changes in chronic illness
- Depression/Anxiety: SSRIs (sertraline, citalopram) and SNRIs (venlafaxine) are most commonly used and generally well-tolerated in PD
- Apathy: Pramipexole (dopamine agonist) has shown benefit; rivastigmine helps apathy in PD with cognitive impairment
- Psychosis: Pimavanserin (Nuplazid) — the only FDA-approved antipsychotic specifically for PD psychosis; does not worsen motor function
- Impulse control disorders: Reduce or discontinue dopamine agonists; naltrexone has been studied as an add-on
- Cognitive decline: Rivastigmine (Exelon) is FDA-approved for PD dementia; donepezil used off-label
Family members and caregivers of PD patients frequently experience high rates of burnout, depression, and anxiety. Caregiver wellbeing should be an integral part of the PD care plan:
- Caregiver education programs through the Parkinson's Foundation and Michael J. Fox Foundation
- Respite care services and community support programs
- Online and in-person caregiver support groups
- Couples and family therapy to address relationship changes
- Self-care planning and professional counseling for caregivers
Ping Pong Therapy
Table tennis as a neurological intervention for Parkinson's disease
Neuroplasticity Mechanisms
Table tennis demands rapid, precise responses to unpredictable ball trajectories — challenging cerebellar timing, visual-motor integration, and executive function simultaneously. This multi-domain stimulation appears to drive neuroplasticity in motor and cognitive circuits. The gamified, social format ensures high long-term adherence compared to traditional gym exercise.
Research Evidence
A 2020 pilot study (PMC8299968) showed significant improvements in UPDRS motor scores, balance (Berg Scale), and quality of life after 6 months of twice-weekly table tennis sessions. Larger RCTs are underway. Multiple case studies report dramatic improvements even in advanced PD patients who had plateaued on other interventions.
Find a PingPongParkinson Club
Clubs meet weekly in sports centers, care homes, and community venues. All skill levels are welcome — beginners start with balloon and foam ball exercises. Visit pingpongparkinson.com to find your nearest club or learn how to start one in your community. The organization provides equipment and training for new clubs at no cost.
400+ Clubs Worldwide
Active PingPongParkinson clubs in 31 countries across 6 continents
Multi-Domain Exercise
Simultaneously challenges aerobic fitness, fine motor, cognitive, and social domains
High Adherence
Game-based format achieves significantly higher long-term participation than gym exercise
Community Stories
Experiences from people living with Parkinson's disease
"I was diagnosed at 54. After six months of intensive cycling — three times a week at high intensity — my neurologist told me my UPDRS scores had actually improved. Exercise became my main medication."— Michael, 57, competitive cyclist, diagnosed 2021
"DBS surgery changed my life. I went from barely being able to hold a fork to playing guitar again within weeks of my stimulator being turned on. It's not a cure, but for me it was transformative."— Sandra, 63, musician, DBS implanted 2022
"I joined a PingPongParkinson club two years ago. My balance has improved, my medications seem to work better, and I've made the best friends of my life. Nobody else understands what it's like the way these people do."— David, 68, retired teacher, club member since 2022
"The protein redistribution diet sounds like a small change, but it was transformative. By eating protein only at dinner and keeping breakfast and lunch low-protein, my levodopa works smoothly all day long."— Margaret, 70, diagnosed 2018
Your Action Plan
Steps you can take starting today
See a movement disorder specialist
Not all neurologists have deep expertise in PD. A movement disorder specialist has additional fellowship training specifically in Parkinson's and related conditions. Studies show patients managed by movement disorder specialists have significantly better outcomes. Search via the Parkinson's Foundation provider directory at parkinson.org.
Start exercise — today
Begin a structured exercise program immediately after diagnosis. Exercise is the most evidence-supported intervention for slowing PD progression. Aim for vigorous aerobic exercise — cycling, swimming, treadmill — at least 3 times per week. Find a PD-specialized physiotherapist through the Parkinson's Foundation's provider directory.
Request genetic testing
Genetic testing can identify LRRK2, GBA1, PINK1, and SNCA mutations. This may qualify you for specific clinical trials, inform your prognosis, guide family screening decisions, and enable precision medicine approaches now and in the near future. Discuss genetic counseling with your neurologist.
Explore clinical trials
Visit Fox Trial Finder (foxtrialfinder.michaeljfox.org) and ClinicalTrials.gov to find trials you may qualify for. Even placebo-controlled trials provide excellent monitoring and access to specialist teams. Many trials cover all study-related costs and travel expenses.
Connect with the PD community
Join a Parkinson's support group — in-person or online. The Parkinson's Foundation and Michael J. Fox Foundation have community programs, events, and helplines. PingPongParkinson clubs offer a social, therapeutic environment. Peer support significantly improves quality of life for both patients and caregivers.
Plan for the future — while you're well
Advance care planning is easier when done early: review finances, insurance, employment accommodations, power of attorney, and future living arrangements. Many PD advocacy organizations provide practical planning guides. Having these conversations early significantly reduces stress for you and your family.
Resources and Organizations
Leading international organizations, centers, and tools